5 Stocks to Buy Now Before this 2025 Change
Published: 2024-12-18
Status:
Analyzed
Published: 2024-12-18
Status:
Analyzed
Predictions from this Video
Incorrect: 0
Prediction
Topic
Status
United Healthcare (UNH) to launch 140 new Medicare Advantage plans in 2025.
"United Healthcare is expanding its coverage launching 140 new plans in 2025"
Pending
United Healthcare (UNH) expected to have 8% revenue growth in 2024 and 2025, and 9% annualized earnings growth.
"United Healthcare does show one of the more consistent and higher growth rates of the group at 8% Revenue growth expected this year and next along with 9% annualized earnings growth"
Pending
United Healthcare (UNH) average analyst price target is $643 per share, representing a 17% upside.
"analysts have an average price target of $643 a share about a 17% upside from here"
Pending
CVS Health (CVS) expected to post around 4% revenue growth in 2024 and 2025, with earnings under pressure.
"The market expects CVS to post low single digigit growth around 4% this year and next with with earnings still under pressure from that retail side of the store"
Pending
CVS Health (CVS) average analyst price target is $67 per share, representing a 22% upside.
"analysts have an average Target of $67 a share about 22% higher from here"
Pending
Some analysts predict CVS Health (CVS) could reach $80 per share.
"but some of that as high as $80 each"
Pending
Centene Corp (CNC) expected to post around 3-4% revenue growth in 2024 and 2025, with higher earnings growth.
"growth here is similar to CVS with expectations for around 3 to 4% on Revenue though earnings are expected higher"
Pending
Centene Corp (CNC) average analyst price target suggests 37% upside, with unanimous consensus for higher prices.
"the average analyst Target is for 37% upside with a unanimous consensus for higher prices"
Pending
One analyst predicts Centene Corp (CNC) could see an upside of 61%.
"and one as high as 61% higher"
Pending
Cigna Group (CI) expected to have 25% revenue growth in 2024, then slow to industry rate in 2025, with earnings continuing to rise.
"Signa had very strong growth of 25% in Revenue this year but is expected to slow down to that industry rate this year though earnings are expected to continue Rising"
Pending
Cigna Group (CI) average analyst price targets predict around 25% return, with a minimum of 14% return.
"analyst targets here are for around 25% return with even the lowest estimate a 14% return on these shares"
Pending
Humana Inc (HM) reported solid growth in 2024 but is expected to have only 1.6% sales growth in 2025, while earnings are expected to rebound.
"The company reported solid growth this year but is expected to do nothing next with just 1.6% sales though earnings are expected to continue to rebound"
Pending
Humana Inc (HM) analyst target price is $285 per share.
"with a target of just $285 per share"
Pending
The high analyst target for Humana Inc (HM) is $374 per share.
"even that high Target of $374 a share would still be well below where it's been"
Pending
Medicare spending is estimated to grow at a 5.6% annual pace over the next ten years (2025-2034).
"Medicare spending is estimated to grow at a 5.6% pace over the next decade"
Pending
Medicare Advantage enrollment is expected to exceed 60% of eligible individuals by the end of 2029.
"is expected to rise further to over 60% by the end of the decade"
Pending
The identified Medicare Advantage stocks could see 20% to 40% returns over the next year (2025).
"We could easily see 20 or 40% returns over the next year"
Pending
Medicare Advantage stocks have potential for significant jumps in Q1 2025 due to news on CMS or Medicare Advantage policy changes.
"the potential is there for those big jumps in the first quarter of the year on on any news of changes at the CMS or on those Medicare Advantage policies"
Pending
United Healthcare (UNH) has an average analyst price target of $643, representing about 17% upside from its price at the time of the video.
"analysts have an average price target of $643 a share about a 17% upside from here"
Pending
The author believes United Healthcare (UNH) stock has more upside potential than indicated by current analyst targets.
"I think analysts are behind the curve on this one and there is more upside than that Target would suggest"
Pending
CVS Health (CVS) revenue growth is expected to be around 4% for 2024 and 2025.
"The market expects CVS to post low single digigit growth around 4% this year and next"
Pending
CVS Health (CVS) has an average analyst price target of $67, representing about 22% upside, with some targets as high as $80.
"analysts have an average Target of $67 a share about 22% higher from here but some of that as high as $80 each"
Pending
Centene (CNC) has an average analyst price target for 37% upside, with some targets as high as 61%.
"the average analyst Target is for 37% upside with a unanimous consensus for higher prices and one as high as 61% higher"
Pending
Cigna (CI) has analyst price targets for around 25% return, with a minimum estimated return of 14%.
"analyst targets here are for around 25% return with even the lowest estimate a 14% return on these shares"
Pending
The author believes Humana (HUM) stock will perform better than current analyst expectations.
"I think even the analyst Community is going to be caught surprised on this one"
Pending
Humana (HUM) has an average analyst price target of $285 per share, with a high target of $374 per share.
"with a target of just $285 per share shares reached $535 each last year so even that high Target of $374 a share would still be well below where it's been"
Pending
Five specific Medicare Advantage stocks are predicted to have at least 20% upside to analyst targets.
"I found five stocks in the center of it with 20% upside to analyst Targets"
Pending
Medicare spending is estimated to grow at a 5.6% annual pace over the next 10 years.
"Medicare spending is estimated to grow at a 5.6% pace over the next decade"
Pending
Medicare Advantage enrollment is expected to exceed 60% of eligible individuals by the end of the decade (2030).
"is expected to rise further to over 60% by the end of the decade"
Pending
Medicare Advantage stocks could see 20% to 40% returns over the next year (2025).
"We could easily see 20 or 40% returns over the next year"
Pending